Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:BCTX NASDAQ:OBSV NASDAQ:PLRZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.15-4.2%$1.37$0.88▼$3.40$29.90M0.54180,907 shs84,434 shsBCTXBriacell Therap$3.58-3.8%$3.35$2.60▼$14.68$31.15M1.15164,290 shs63,887 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shsN/APLRZPolyrizon$14.68-4.1%$13.54$2.88▼$18.20$30.59M-1.5938,981 shs117,798 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma-4.17%-8.00%-13.53%+7.48%-62.54%BCTXBriacell Therap-3.76%-4.02%+18.54%-7.73%-56.87%OBSVObsEva0.00%0.00%0.00%0.00%+100.00%PLRZPolyrizon-4.11%+9.39%+22.95%-5.66%+30.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.15-4.2%$1.37$0.88▼$3.40$29.90M0.54180,907 shs84,434 shsBCTXBriacell Therap$3.58-3.8%$3.35$2.60▼$14.68$31.15M1.15164,290 shs63,887 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shsN/APLRZPolyrizon$14.68-4.1%$13.54$2.88▼$18.20$30.59M-1.5938,981 shs117,798 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma-4.17%-8.00%-13.53%+7.48%-62.54%BCTXBriacell Therap-3.76%-4.02%+18.54%-7.73%-56.87%OBSVObsEva0.00%0.00%0.00%0.00%+100.00%PLRZPolyrizon-4.11%+9.39%+22.95%-5.66%+30.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 1.00SellN/AN/ABCTXBriacell Therap 1.00SellN/AN/AOBSVObsEva 0.00N/AN/AN/APLRZPolyrizon 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest OBSV, BCTX, ABVC, and PLRZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026BCTXBriacell Therap Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/13/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/26/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/15/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/11/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/21/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/4/2026PLRZPolyrizon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/1/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$510K58.63N/AN/A$0.52 per share2.21BCTXBriacell TherapN/AN/AN/AN/A$9.20 per shareN/AOBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/APLRZPolyrizonN/AN/AN/AN/A$13.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$7.91M-$0.40N/AN/AN/AN/A-62.46%-39.99%8/18/2026 (Estimated)BCTXBriacell Therap-$26.31M-$7.92N/AN/AN/AN/A-153.53%-129.26%N/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/APLRZPolyrizon-$3.34MN/AN/AN/AN/AN/AN/AN/AN/ALatest OBSV, BCTX, ABVC, and PLRZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/9/2026Q3 2026BCTXBriacell TherapN/A-$0.99N/A-$0.99N/AN/A5/18/2026Q1 2026ABVCABVC BioPharmaN/A-$0.06N/A-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/ABCTXBriacell TherapN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.120.12BCTXBriacell TherapN/A7.077.07OBSVObsEvaN/A0.610.61PLRZPolyrizonN/A29.0329.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%BCTXBriacell Therap15.42%OBSVObsEva17.52%PLRZPolyrizonN/AInsider OwnershipCompanyInsider OwnershipABVCABVC BioPharma19.00%BCTXBriacell Therap0.74%OBSVObsEva14.40%PLRZPolyrizonN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3026.00 million21.06 millionNot OptionableBCTXBriacell Therap88.70 million8.64 millionNo DataOBSVObsEva5077.97 million66.74 millionNot OptionablePLRZPolyrizonN/A2.08 millionN/AN/AOBSV, BCTX, ABVC, and PLRZ HeadlinesRecent News About These CompaniesPolyrizon (NASDAQ:PLRZ) Shares Up 1.7% - What's Next?July 22 at 2:20 AM | americanbankingnews.comPolyrizon Shareholders Approve New Executive Compensation Policy on July 13, 2026July 13, 2026 | tipranks.comPolyrizon Clears Key Safety Milestone for NASARIX Allergy Nasal SprayJuly 2, 2026 | tipranks.comPolyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)July 2, 2026 | msn.comPolyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting ...July 2, 2026 | enidnews.comEPolyrizon Announces Successful Biocompatibility Results for NASARIX Allergy Blocker Nasal SprayJuly 2, 2026 | quiverquant.comQPolyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical TrialJuly 2, 2026 | globenewswire.comPolyrizon Wins Central IRB Nod for First NASARIX Allergy Blocker TrialJune 29, 2026 | tipranks.comPolyrizon Receives Central IRB Approval for First Human Clinical Trial of NASARIX Allergy BlockerJune 29, 2026 | quiverquant.comQPolyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical TrialJune 29, 2026 | globenewswire.comPolyrizon Announces U.S. Publication of Mucoadhesive Nasal Drug Delivery PatentJune 17, 2026 | tipranks.comPolyrizon Ltd.: Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery PlatformJune 17, 2026 | finanznachrichten.dePolyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery PlatformJune 17, 2026 | globenewswire.comPolyrizon Launches Key Human Study to Advance NASARIX Allergy Blocker Toward FDA PathwayJune 15, 2026 | tipranks.comPolyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory PathwayJune 15, 2026 | globenewswire.comPolyrizon Ltd.: Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery TechnologyJune 12, 2026 | finanznachrichten.dePolyrizon Marches on European PatentJune 11, 2026 | baystreet.caPolyrizon Wins European Patent Publication for Mucoadhesive Nasal Drug Delivery PlatformJune 10, 2026 | tipranks.comPolyrizon Ltd. Announces Publication of European Patent Application for Innovative Nasal Drug Delivery TechnologyJune 10, 2026 | quiverquant.comQPolyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery TechnologyJune 10, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOBSV, BCTX, ABVC, and PLRZ Company DescriptionsABVC BioPharma NASDAQ:ABVC$1.15 -0.05 (-4.17%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.15 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Briacell Therap NASDAQ:BCTX$3.58 -0.14 (-3.76%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$3.54 -0.04 (-0.98%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Polyrizon NASDAQ:PLRZ$14.68 -0.63 (-4.11%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$14.86 +0.19 (+1.26%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
